OncoGenex Pharma (OGXI) Announces Custirsen Phase 3 Missed Primary Endpoint in NSCLC
Tweet Send to a Friend
OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced results from the final analysis of the Phase 3 ENSPIRIT trial of custirsen in ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
